Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to “Strong-Buy” at UBS Group

Posted by Brian Himes on Oct 17th, 2026

UBS Group upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) to a strong-buy rating in a report published on Wednesday morning,Zacks reports.

ALNY has been the subject of several other research reports. BMO Capital Markets restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $350.00 to $345.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Four research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $364.95.

View Our Latest Report on ALNY

Alnylam Pharmaceuticals Stock Down 0.9%

Shares of ALNY stock traded down $2.20 on Wednesday, reaching $231.83. 1,404,802 shares of the company were exchanged, compared to its average volume of 1,301,571. The company has a market cap of $31.02 billion, a price-to-earnings ratio of 43.09 and a beta of 0.28. The company has a 50-day moving average of $239.35 and a 200-day moving average of $274.34. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals has a one year low of $197.81 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.51) EPS. Analysts anticipate that Alnylam Pharmaceuticals will post 6.68 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the company. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $50,773,000. Silvant Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth about $5,456,000. Hsbc Holdings PLC increased its holdings in Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after acquiring an additional 16,503 shares during the last quarter. Finally, Wealthfront Advisers LLC bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $2,876,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.